Telegram RegisterThe public register of Telegram
Telegram profile photo for 허혜민의 제약/바이오 소식통

Channel

허혜민의 제약/바이오 소식통

@huhpharm

On this record: Topic · Observations · Channels linked by matching posts · Growth · Engagement · What this channel posts · Posts · Citations · Telegram's recommendations · Cite this entry

24,265subscribers

+346 since we began measuring on 6 August 2026

Risers and fallers across the register · movement among entries of 10,000–31,623.

Register entry

Telegram ID-1001381339396
TypeChannel
Username@huhpharm
Description제약/바이오 뉴스, 업데이트, 발간자료 공유
Created12 July 2020 — measured — cross-checked against a third-party dataset (ext.tg_channel)
First recorded6 August 2026
Last confirmed live9 November 2026
Measurements held62
Confirmed unchanged1 time, most recently 9 November 2026
On Telegramt.me/huhpharm

Topic

Other / unclassifiable — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 10 September 2026 and assigned it the closest of 31 fixed categories, at 64% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and the other topics.

Observations

These are measurements, not verdicts. Each one below states something we counted, alongside the evidence it was counted from, so you can check it rather than take it. None of them is graded: every observation this register holds is recorded at severity 0, because the precision of the detectors behind them has not been measured yet, and a rating we cannot support is worse than none. Read each as a fact about the data, not as a judgement about the channel. How we measure.

Content that also appears on other registered channels

Posts published here appear in near-verbatim form on 12 other registered channels. This entry also sits inside a group of 12 channels linked by matching posts, directly or through other channels in the group; two members of the group may share no posts with each other. The matching is on the text itself, not on Telegram’s forward marker, so it finds a copy whether or not it was labelled as one.

Matching posts — open both and compare (6 of the pairs behind the counts below)
Posted firstThenOverlapGap
@pharmbiohana/1173327 Oct 2026, 07:08 UTC@huhpharm/11929 · this entry27 Oct 2026, 07:11 UTC1.003 minutes
@huhpharm/11892 · this entry19 Oct 2026, 01:52 UTC@Yeouido_Lab/3823219 Oct 2026, 01:52 UTC1.00under a minute
@mnJeong_BIO/401230 Oct 2026, 04:47 UTC@huhpharm/11952 · this entry30 Oct 2026, 05:02 UTC1.0015 minutes
@huhpharm/11557 · this entry4 Aug 2026, 22:35 UTC@EarlyStock1/78524 Aug 2026, 22:37 UTC1.002 minutes
@huhpharm/11911 · this entry22 Oct 2026, 12:05 UTC@EarlyStock1/838722 Oct 2026, 13:35 UTC1.001.5 hours
@huhpharm/11942 · this entry29 Oct 2026, 13:06 UTC@EarlyStock1/842629 Oct 2026, 13:25 UTC1.0019 minutes
Channels this entry shares post bodies with, where at least one matching post pair has no forward credit between the two channels, or to a common source, recorded in our data
ChannelMatching postsText overlapTypical gapPublished first
@pharmbiohana58 (8/8 hand-verifiable sample passed)1.0019 minutesthis entry (42–16)
@Yeouido_Lab39 (8/8 hand-verifiable sample passed)1.005 minutesthis entry (20–19)
@mnJeong_BIO17 (8/8 hand-verifiable sample passed)1.005 minutesthis entry (13–4)
@KiwoomResearch40 (8/8 hand-verifiable sample passed)0.99under a minutethis entry (40–0)
@bio_shinhan27 (8/8 hand-verifiable sample passed)1.005 minutes@bio_shinhan (18–9)
@EarlyStock18 (8/8 hand-verifiable sample passed)1.0014 minutesthis entry (7–1)
@bioksm16 (8/8 hand-verifiable sample passed)1.008 minuteseven
@bdragon08087 (7/7 hand-verifiable sample passed)1.0020 minutesthis entry (6–1)
@insidertracking6 (6/6 hand-verifiable sample passed)1.00under a minutethis entry (4–2)
@Ten_level12 (8/8 hand-verifiable sample passed)1.005 minutes@Ten_level (8–4)
@alteogenIR8 (8/8 hand-verifiable sample passed)1.00under a minute@alteogenIR (8–0)
@stoner87407 (7/7 hand-verifiable sample passed)1.004 minutes@stoner8740 (6–1)

Text overlap is the Jaccard coefficient over the set of distinct three-word phrases in the two bodies: 1.00 is identical wording, and the threshold for counting a pair at all is 0.70. Candidates are generated by simhash LSH (4 x 16-bit bands, exact Hamming <= 3) verified against the bodies with Jaccard over the SET of distinct 3-word shingles. Published first counts which side of each matching pair carries the earlier timestamp — in this corpus, which is the limitation directly below.

What this cannot establish

MEASURED, DOMINANT ERROR SOURCE: a post ingested before 2026-08-06 may have carried a forward header that was not recorded. A 45-pair hand-check against live t.me pages found 14 (31%) where the live page shows a forward header naming the other channel and the database has none, plus 4 more (9%) naming a third party. The text match itself was wrong 0 times out of 45. Read attribution_capture.items_in_trusted_window before treating the unattributed count as a claim.

Telegram lets a channel forward a post with a header naming the source, and we only began reliably recording that header on 2026-08-06. 27 of the 27 matches recorded here fall after that date and carried no header when we read them. The rest predate reliable capture and are not evidence either way.

“Published first” means first in this corpus. We hold 299 comparable posts for this entry, running 4 August 2026 to 10 November 2026. A channel we have read one page deep will look younger than a neighbour we have read in full, and the order would flip with no change in the underlying facts.

The detector’s own notes on this observation, as it recorded them. Names in this_style are fields of the underlying evidence record, which the plain-English paragraphs above read out for this entry.

  • Verbatim republication has three causes and the text separates only two: a clone/mirror, unattributed copy-paste, or BOTH channels copying a common third source that neither attributes. The spread filter (content held by at most 8 channels) reduces the third and does not remove it.
  • 'Earliest' means earliest IN THIS CORPUS. A channel ingested one page deep will look younger than a neighbour ingested in full; corpus_coverage above is there to be checked before the direction is believed.
  • shared_verified_est extrapolates the sampled pass rate over the full narrow match count; sampled/passed are the numbers actually measured.
  • Absence of a forward header is not proof of intent: Telegram lets a channel disable forward attribution, and a credit written in the body is not parsed as attribution here (mention_edge_either_way above is the closest available signal).

Of the group of 12 channels, the one whose matching posts we hold earliest is @alteogenIR. That is a statement about our reading window, not a claim of authorship.

Recorded under the keys clone_copy · clone_mutual · clone_source, last confirmed 11 November 2026. An observation that a later pass no longer finds is cleared, and a cleared observation is removed from this page rather than being shown struck through — we do not keep publishing a claim we have withdrawn. Dispute an observation.

Channels linked by matching posts

This channel is in a group of 12 registered channels linked by matching posts, directly or through other channels in the group. This channel may share no posts with some of the channels listed below, and listed channels may share none with each other. Links are found by comparing text fingerprints across every channel on the register.

Which channel, if either, published first is deliberately not shown in this list. “First” could only mean first in our own crawl, which depends on how deep we happened to reach into each channel’s history, not on when the content was actually first posted. Our one hand-check read 45 of the highest-confidence flagged pairs against the live Telegram pages. In 18 of them the live page showed a “Forwarded from” credit that our database had no record of, so reading that pair as an unattributed copy was wrong; the check did not measure who published first. This list is ordered by subscriber count, the same as every other listing on this site, never by which channel we think came first. Near-verbatim matching has several ordinary explanations besides copying — a channel mirroring itself, an unattributed repost, or two channels independently repeating the same wire story — and this measurement cannot tell those apart. How this is measured.

Growth

23,89024,30824,09924,2656 August 20269 November 2026
62 measurements spanning 96 days, net +346. Dots are measurements; the straight line between them is drawn to join them, not to claim we know the path taken in between — snapshots are recorded only when a count changes, so gaps mean “no change observed”, never “interpolated”. The vertical axis spans 23,827–24,371 and does not start at zero.
Measurement log — every subscribers count we have recorded, most recent 20 of 62
Measured (UTC)SubscribersChange
9 Nov 2026, 21:5624,265+1
8 Nov 2026, 14:5824,264+3
7 Nov 2026, 08:5624,261-5
6 Nov 2026, 09:4824,266-2
5 Nov 2026, 10:4624,268+8
4 Nov 2026, 12:1824,260+4
3 Nov 2026, 15:1624,256-4
2 Nov 2026, 15:0824,260+2
1 Nov 2026, 16:1724,258-2
31 Oct 2026, 14:3624,260-5
30 Oct 2026, 13:4824,265+9
29 Oct 2026, 13:3624,256-3
28 Oct 2026, 16:0824,259-7
27 Oct 2026, 17:0424,266-3
26 Oct 2026, 15:1924,269-2
25 Oct 2026, 13:2724,271-6
23 Oct 2026, 11:3824,277-9
22 Oct 2026, 08:3524,286-2
21 Oct 2026, 04:0024,288-6
20 Oct 2026, 01:1824,294first reading

Engagement

360 posts held, back to 4 August 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 129 pages of Telegram’s post history, 20 posts per page.

ERR · 30 days
17.9%
avg views ÷ 24,265 subscribers
Avg views / post
4,330
140 posts measured
Reaction rate
—
this channel exposes no reaction counts
Posts in window
140
of 360 held

ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.

ER is defined industry-wide as (forwards + reactions + comments) ÷ views — note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate.

What these figures were computed from
WindowRolling 30 days · latest post in window 10 November 2026
Posts held360 (4 August 2026 – 10 November 2026)
Views total606,880
Reactions total—
Forwards / commentsnot exposed by the public surface — not measured, not estimated
Readings taken11 Nov 2026, 05:33 UTC

Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.

Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.

Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.

What this channel posts

Photos
≈1,960
Videos
≈2
Links
≈3,720

Lifetime counters from Telegram’s own channel header, read 11 November 2026 — not the date at the top of this page, which is when the subscriber count was last read. A count marked ≈ was rounded by Telegram before we ever saw it — t.me prints these counters in full below 1,000 and to three significant figures above, so ≈142,000 means somewhere between 141,500 and 142,499.

Recent posts

Telegram’s own ‘edited’ marker: 7 of 140 posts held from the last 30 days (5.00%) carried it when this register last read them. The marker says a post was changed after publishing, not what it said before — this register holds the earlier wording only where an edit fell between two of its own reads (see the edit ledger and how it is measured).

10 Nov 2026, 22:48 UTC≈3,430 viewsread 11 November 2026

★ [키움 허혜민] ★ 한올바이오파마 (009420), 서프라이즈한 RA 임상 결과 [키움 제약/바이오 / 허혜민] ◆ 애널리스트 코멘트 투자의견 BUY, 목표가 8만원 유지 Immunovant의 IMVT-1402의 난치성 류마티스관절염 2b상 성공 발표에 당일(11/9) +15% 상승, 시가총액 $968mn 증가. 동사 역시 전일(11/10) 주가 +26% 상승, 시가총액 5,020억원 증가. 약물의 긴 반감기에 따른 위약군과의 유의한 차이 확보가 어려울 것으로 예상됐으나, 기대치 상회하는 긍정적 결과 확인. 12/9일 Investor Day에서 후속 RA 개발 전략 구체화 및 ‘27년 GD·MG 탑라인 결과 발표 등 임상 모멘텀이 지속될 것으로 예상. 키움 제약/바이오 소식통 → https://t.me/huhpharm ★ 보…

Signed Jonghyun Kim

10 Nov 2026, 22:48 UTC≈2,260 viewsread 11 November 2026

★ [키움 허혜민] ★ 이뮤노반트 (IMVT.US): Deeper is better를 증명한 임상 [키움 제약/바이오 / 허혜민] ◆ 애널리스트 코멘트 - 11/9일 D2T RA Period 2에서 IMVT-1402 600mg 1차 평가지표 충족. 300mg은 위약과 결과 동일. IgG 감소 깊이가 효능을 좌우한다는 가설 증명 - D2T RA 2차 지표 미달과 CLE·쇼그렌 개발 중단으로 적응증 4개로 압축은 아쉬움 - 주가는 발표 당일 약 15% 상승. 2027년 GD·MG 탑라인 기대 키움 제약/바이오 소식통 → https://t.me/huhpharm ★ 보고서 링크: https://bbn.kiwoom.com/rfCC1741 * 컴플라이언스 검필 * 본 정보는 키움증권 리서치센터에서 고객분들에게 발송하는 정보입니다.

Signed Jonghyun Kim

10 Nov 2026, 22:42 UTC≈2,150 viewsread 11 November 2026

26/11/11 (수) 키움 제약바이오 데일리 💊 [제약/바이오 Analyst 허혜민, RA 김종현] 키움 제약/바이오/의료기기 소식통: t.me/huhpharm <‍📈 주요 지수 등락> * 코스피 +4.39% vs 코스피 제약 -1.84% * 코스닥 +4.48% vs 코스닥 제약 +2.66% * S&P500 -0.38% vs XBI -1.17% * 나스닥 -0.74% vs NBI -0.86% <‍🇰🇷 국내 주요 뉴스 🔥> *괄호 안은 전일 수익률 ★ 알테오젠 부담 덜었다…할로자임 피하주사 특허 미국서 또 제동 (+3.86%) - MSD, PGR 12건 승리…남은 2건 19일께 결론 -> https://tinyurl.com/24d757j4 ▶ [단독] 황만회 애드바이오텍 대표, 사기 업무방해 혐의 피소 (-24.50%) -> htt…

Signed Jonghyun Kim

10 Nov 2026, 08:01 UTC≈1,740 viewsread 11 November 2026

안녕하세요, 올릭스 커뮤니케이션실입니다. 당사의 황반변성 치료제 ‘OLX301A’가 뉴질랜드 보건장애윤리위원회(HDEC)로부터 임상 2a상 윤리심의 승인을 획득하여 안내드립니다. 앞서 안내드린 바와 같이 뉴질랜드에서 임상시험을 진행하기 위해서는 HDEC과 Medsafe(의약품 규제기관)의 승인을 각각 받아야 합니다. 당사는 지난 9월 30일 Medsafe에 임상시험계획 승인을 신청하였으며, 현재 심사 결과를 기다리고 있습니다. 지난 10월 호주에서 임상 2a상 시험계획을 승인받은 데 이어, 이번 뉴질랜드 윤리심의 승인으로 다국가 임상 개발을 위한 절차를 추가로 완료하게 되었습니다. 회사는 앞서 미국 식품의약국(FDA)에도 임상시험계획을 제출하는 등 글로벌 임상 개발에 더욱 박차를 가하도록 하겠습니다. 앞으로도 각국의 임상 개발 진행 …

Signed 혜민 허

10 Nov 2026, 04:54 UTC≈2,700 viewsread 11 November 2026

알테오젠 파트너 MSD, 할로자임 美 특허 12건 무효 판단…남은 2건 결론 임박 https://www.thebionews.net/news/articleView.html?idxno=30076

Signed 혜민 허

10 Nov 2026, 02:43 UTC≈1,930 viewsread 11 November 2026

안녕하세요 디앤디파마텍입니다. 당사가 개발 중인 MASH 치료제 자보페그두타이드 임상 2상 결과가 미국간학회(AASLD) 연례 학술 대회 'The Liver Meeting 2026'에서 'Best of The Liver Meeting' 초록으로 선정되어 이와 관련한 보도자료 공유 드립니다. 디앤디파마텍 MASH 치료제 ‘자보페그두타이드’, AASLD 2026 ‘Best of The Liver Meeting’ 선정 ▶️세계 최고 권위 미국간학회(AASLD) 피날레 ‘MASLD Debrief’ 세션에서 핵심 임상 연구로 조명 ▶️2,900여편의 전체 초록 중 엄선된 주요 연구로 소개, MASH 임상시험 핵심 성과 부분 단 4건에 포함 ▶️과거 마드리갈·아케로 등 글로벌 MASH 신약 선정 이력, 글로벌 기술이전 협상에도 긍정적 영향 기대 …

Signed 혜민 허

10 Nov 2026, 00:20 UTC≈1,480 viewsread 11 November 2026

#알테오젠 최근 주가 하락은 과도하다 판단되어 알테오젠 2대주주인 형인우외 특수관계인 1인은 알테오젠 주식을 추가 매수 하였습니다. 주가 회복에 조금이나마 도움이 되길 희망합니다. 형인우 2026.11.09 매수 12,000주 167,978원 2026.11.10 매수 10,000주 174,431원 염혜윤(특수관계인) 2026.11.09 매수 2,000주 167,184원 2026.11.10 매수 3,000주 175,017원 총합계 : 27,000주 총평균단가 : 171,091원 총금액 : 4,619,465,000 원 (주)스마트앤그로스 대표 형인우 드림.

Signed Jonghyun Kim

9 Nov 2026, 22:38 UTC≈3,690 viewsread 11 November 2026

26/11/10 (화) 키움 제약바이오 데일리 💊 [제약/바이오 Analyst 허혜민, RA 김종현] 키움 제약/바이오/의료기기 소식통: t.me/huhpharm <‍📈 주요 지수 등락> * 코스피 -0.81% vs 코스피 제약 -0.28% * 코스닥 -0.82% vs 코스닥 제약 -1.67% * S&P500 +2.35% vs XBI +3.08% * 나스닥 +2.74% vs NBI +2.73% <‍🇰🇷 국내 주요 뉴스 🔥> *괄호 안은 전일 수익률 ★ 美 이뮤노반트 “한올 L/O ‘IMVT-1402’, 난치성 RA 임상서 1차 지표 충족” (+15.13%) - 600㎎ 투여군 28주차 ACR20 반응률 92.5%…위약은 75.6% 기록 - 올 하반기 FDA 논의 예정…‘쇼그렌병’은 2상 이후 추가 개발 가능성 낮아 -> https:/…

Signed Jonghyun Kim

9 Nov 2026, 12:43 UTC≈3,990 viewsread 11 November 2026
Photo

[키움 허혜민] 이뮤노반트, 류마티스관절염 2b상 1차 지표 충족. 쇼그렌증후군 후속 개발 중단 가능성 IMVT-1402의 치료가 어려운 류마티스관절염(D2T RA) 임상 1차 지표 달성 발표. 반면 쇼그렌증후군(SjD) 2상 이후 추가 개발 가능성 낮다고 언급 RA 170명 대상 16주간 IMVT-1402 600mg 공개 투여 후, ACR20 반응 기준 충족한 환자 117명 600mg(n=40), 300mg(n=36), 위약(n=41)에 무작위 배정하는 치료 중단·유지 설계 28주차 ACR20 반응 유지율은 600mg 92.5% vs 위약 75.6%(p=0.0139)로 1차 평가지표 충족. 반면 300mg은 75.0%로 위약 대비 유의한 차이 없음(p=0.9426) ACR50은 80.0% vs 56.1%(명목 p=0.0117), AC…

Signed 혜민 허

9 Nov 2026, 10:48 UTC≈3,290 viewsread 11 November 2026

MSD, 인제니아 'IGT-302' 녹내장 적응증 공동연구 계획 종료 MSD, 옵션 미행사 결정 GT-427 글로벌 3상·IGT-303 신장질환 임상은 지속 출처 : 히트뉴스(https://www.hitnews.co.kr) https://www.hitnews.co.kr/news/articleView.html?idxno=80630

Signed 혜민 허

9 Nov 2026, 03:37 UTC≈2,960 viewsread 11 November 2026

안녕하세요 디앤디파마텍입니다. 당사는 최근 미국 덴버에서 개최된 미국간학회 AASLD 연례학술대회 'The Liver Meeting 2026'에서 MASH 치료제 '자보페그두타이드' 임상2상 결과를 구두 발표했습니다. 이와 관련한 보도자료 공유 드립니다. 디앤디파마텍 MASH 치료제 ‘자보페그두타이드’ 임상 2상 결과, 美 AASLD 2년 연속 ‘Late-Breaking’ 구두 발표 ▶️세계 최고 권위 미국간학회(AASLD The Liver Meeting® 2026)에서 48주 최종 임상 결과 구두 발표 ▶️섬유화 개선 등 조직생검 결과 외, 지방간·간 효소·체중·혈당 등 포괄적 대사 지표 동시 개선 확인 ▶️학회 기간 글로벌 파트너사 대면 미팅 진행 등 기술이전 논의 가속화 전망 [2026-11-09] GLP-1 계열 신약 개발 전문…

Signed 혜민 허

9 Nov 2026, 01:29 UTC≈2,260 viewsread 11 November 2026
Photo

✅ 알테오젠 공식 입장문 (홈페이지) https://www.alteogen.com/kr/sub/ir/information.php?mode=view&bid=2&idx=519&page=1

Signed 혜민 허

Showing the 12 most recent of 360 posts we hold for @huhpharm. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.

Forward network

Republishes

Channels on the register whose posts this channel has forwarded.

AWAKE - 실시간 주식 공시 정리채널
@darthacking · 65,571
25 posts
더바이오 뉴스룸
@thebio111 · 6,533
16 posts
알테오젠 IR
@alteogenIR · 9,805
10 posts
올릭스(주) - OliX Pharmaceuticals
@olix_official · 3,848
7 posts
리가켐바이오 IR/PR 공식 채널
@SHIDGL · 9,885
4 posts
DAJU - 기업 공시
@daju_dart · 4,569
4 posts
디앤디파마텍 공식 IR 채널
@dndpharmatech · 3,614
4 posts
글로벌 바이오헬스케어 뉴스
@global_biohealthcare_news · 4,589
4 posts
[키움증권]스몰캡은 키움
@kwsmlcp · 601
4 posts
Yeouido Lab_여의도 톺아보기
@Yeouido_Lab · 43,456
3 posts
한경바이오인사이트
@hkbioinsight · 4,255
3 posts
독립리서치 밸류파인더
@valuefinder · 12,353
3 posts
더파마 뉴스·인사이트| THE PHARMA
@BBAinsights · 1,136
2 posts
에이프릴바이오 공식IR채널: 리레이팅 2026
@aprilbioipr · 4,394
2 posts
지아이이노베이션 공식 IR
@GIInnovation · 2,117
1 post
여의도스토리 Ver2.0-习近平是个狗东西
@YeouidoStory2 · 57,966
1 post
바이오헬스 히트뉴스
@hitnews_telegram · 811
1 post
아이엠바이오로직스 IR/PR
@imbiologics_official · 563
1 post
미국 주식 인사이더 🇺🇸 (US Stocks Insider)
@insidertracking · 74,015
1 post
이지스스트레티지 리서치
@jeilstock · 26,244
1 post
키움증권 미국주식 톡톡
@kwusa · 36,213
1 post
📰 실시간 속보 단독 뉴스
@news_kor · 15,618
1 post
@오스코텍 IR/PR 공식 채널
@oscotecinc · 590
1 post
큐리언트 스토리
@qurient · 1,491
1 post
[시그널랩] Signal Lab 리서치
@siglab · 10,749
1 post
키움증권 신민수 의료기기 기록보관소
@sms_archive · 3,320
1 post
돈되는 주식뉴스 : 뉴스매매자가 공유해주는 찐뉴스
@stocknews_today · 1,318
1 post
🗽엄브렐라(Umbrella Research) 리서치+ 네프콘 옆집부자형 since 2020
@umbrellaresearch · 13,060
1 post

Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.

Mentions

Named by 10 registered channels — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.

A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.

Channels Telegram recommends alongside this one

Telegram’s own answer, not this register’s. When this register asks Telegram’s API what is similar to this channel, this is the list it returns, in the exact order Telegram returns it — never re-sorted by subscribers or by anything else this register measures. The relationship, and the order, are Telegram’s; we record them and date them, and make no claim of our own about which of these channels actually resemble this one.

김찰저의 관심과 생각 저장소
@kimcharger · 25,264
#1
AWAKE - 52주 신고가 모니터링
@awake_realtimeCheck · 22,874
#2
한양증권 제약/바이오 오병용
@bdragon0808 · 13,488
#3
올바른
@allbareun · 12,174
#4
미국 제약-바이오 주식/약장수
@yakjangsu · 11,375
#5
미래에셋 제약/바이오 김승민
@bioksm · 14,992
#6
Stock Trip
@stocktrip · 7,238
#7
글로벌바이오아저씨
@choaz1 · 6,957
#8
쩜상리서치
@upper_limit_price · 7,954
#9
리가켐바이오 IR/PR 공식 채널
@SHIDGL · 9,885
#10
Pluto Research
@hedgehara · 19,579
#11
상장기업 수사대 ☎️
@cyber_rangers · 16,905
#12
선수촌
@athletes_village · 22,138
#13
BUYagra
@psychotherapy101 · 5,925
#14
도PB의 생존투자
@survival_DoPB · 22,062
#15
주식 급등일보🚀급등테마·대장주 탐색기 | Korean Stocks
@FastStockNews · 128,822
#16
제약/바이오/미용 원리버 Oneriver
@pharmbiohana · 29,759
#17
Yeouido Lab_여의도 톺아보기
@Yeouido_Lab · 43,456
#18
영리한 황소
@stockinvcowcow · 13,370
#19
Buff
@bufkr · 21,585
#20
그로쓰리서치(Growth Research) [독립리서치]
@growthresearch · 40,090
#21
YM리서치
@ym_research · 39,840
#22
[충간지의 글로벌 의료기기/디지털 헬스/로보틱스 연구소]
@globalmedtech · 12,054
#23
가치투자클럽
@corevalue · 67,126
#24
여의도스토리 Ver2.0-习近平是个狗东西
@YeouidoStory2 · 57,966
#25
Macrotrader - 금융치료
@slsyphus · 4,443
#26
Financial Magazine
@hanagae · 4,599
#27
타점 읽어주는 여자(타자)
@tazastock · 40,945
#28
빠르고 정확한 주식정보방
@fastest_info1 · 13,620
#29
유진투자증권 산업분석실 테크/인프라팀
@eugene2team · 7,034
#30
AWAKE - 마켓 브리핑
@awake_schedule · 17,427
#31
잠실개미&10X’s N.E.R.D.S
@jake8lee · 17,222
#32
다올 의료기기/화장품 박종현
@alexppark · 8,596
#33
조기주식회 공부방
@EarlyStock1 · 24,379
#34
탐방봇
@TambangVot · 8,388
#35
실시간 주식 뉴스
@realtime_stock_news · 36,964
#36
BioMoment-Oncology
@biomoment · 3,714
#37
바이오도 간다!
@kkk595959 · 5,696
#38
바이오스펙테이터
@biospectatorT · 5,851
#39
바이오 탐색대
@PathfinderOfBio · 1,079
#40
돼지바
@bbong_tta · 12,887
#41
호그니엘
@hogniel · 15,354
#42
💯똥밭에 굴러도 주식판
@daegurr · 23,776
#43
한투증권 미국/중국전략 정정영
@G2strategy · 16,724
#44
텐렙
@Ten_level · 16,994
#45
야자반 - Y.Z. stock
@yaza_stock · 13,053
#46
양파농장
@Onionfarmer · 16,148
#47
범송공자 X 29PER
@bumsong2 · 13,449
#48
投資, 아레테
@mstaryun · 18,785
#49
기술적 분석으로 보는 주식시장 (by 소라게아빠)
@hermitcrab41_1 · 21,453
#50
에테르의 일본&미국 리서치
@aetherjapanresearch · 34,448 (as read 16 September 2026)
#51
실전매매전략 : 마켓타이밍
@stockgrandmaster · 11,057
#52
CTT Research
@CTTResearch · 6,853
#53
게이머 강석오 [Gamer Seoko Kang]
@seokokang · 5,880
#54
간절한 투자스터디카페
@desperatestudycafe · 18,510
#55
시장 이야기 by 제이슨
@bumgore · 35,370
#56
TRENDSETTER GLOBAL
@TRENDSETTERVERSION2 · 3,883
#57
루팡
@bornlupin · 49,242
#58
Rafiki research
@rafikiresearch · 20,654
#59
AWAKE - 실시간 주식 공시 정리채널
@darthacking · 65,571
#60
디일렉(THEELEC)
@theelec · 10,812
#61
선진짱 주식공부방
@sunstudy1111 · 55,188
#62
투자의 빅 픽처를 위한 퍼즐 한 조각
@investment_puzzle · 14,298
#63
테크밸리 Insight
@triple_stock · 13,408
#64
엄브렐라리서치 Jay의 주식투자교실
@Jstockclass · 26,513
#65
하나 중국/신흥국 전략 김경환
@HANAchina · 35,273
#66
이지스스트레티지 리서치
@jeilstock · 26,244
#67
재야의 고수들
@gaoshoukorea · 41,200
#68
한국투자증권/기관영업부/이민근
@mk81_koreainvestment · 16,681
#69
TNBfolio
@TNBfolio · 25,170
#70
히스토리투자자문 채상욱
@aptvalueprice · 10,361
#71
YIELD & SPREAD
@yieldnspread · 22,089
#72
[메리츠 Tech 김선우, 양승수, 김동관]
@merITz_tech · 24,795
#73
신영증권 박소연
@sypark_strategy · 29,259
#74
반붐온? 방붐온?
@cpshelter · 5,377
#75
뺀지뤼의 SKLab.(스크랩)
@bbanjil · 10,672
#76
레드버드 기업분석
@redbirdstock · 10,747
#77
Thesis
@thesis_true · 2,245
#78
지휘통제실
@Fire_Direction_Center · 5,293
#79
키움 반도체,이차전지 PRIME☀️
@kiwoom_semibat · 12,750
#80
여의도 감성투자
@ygamsung · 6,745
#81
[니커 게임/엔터]
@Nicker0122_1 · 4,024
#82
🗽엄브렐라(Umbrella Research) 리서치+ 네프콘 옆집부자형 since 2020
@umbrellaresearch · 13,060
#83
주식 다람이
@stockDaram2 · 5,018
#84
메리츠 전략 이수정
@KrystalDopamine · 11,933
#85
유진투자증권 코스닥벤처팀
@SmallCap · 22,994
#86
마산창투
@PRROEresearch · 4,656
#87
Nihil's view of data & information
@viewofdata · 13,457
#88
아트합시다.
@Korea_value · 5,467
#89
DAOL 조선/기계/방산 | 최광식
@HI_GS · 17,079
#90
피카츄 아저씨⚡️
@pikachu_aje · 24,923
#91
제이지의 투자이야기
@JgrowthInv · 2,999
#92
[미래 임희석] 인터넷/SW/게임
@mirae_internet · 8,154
#93

Read from Telegram’s recommendation API, most recently 16 September 2026. Telegram holds a list like this for a small and growing share of the register — how this is measured, and why most channel pages show nothing here.

Appears in Telegram’s recommendations for other channels

The reverse of the list above, and a different kind of signal. This does not require this channel to have ever been asked about directly — each row below is a channel we DID ask Telegram about, whose Telegram-generated list happened to include this one. A channel can appear here with an empty list above it, because being named by someone else’s query is independent of having been queried itself.

제약/바이오/미용 원리버 Oneriver
@pharmbiohana · 29,759
Telegram ranks this channel #27 of 89 here — alongside 88 others — read 7 September 2026
키움증권 미국주식 톡톡
@kwusa · 36,213
Telegram ranks this channel #53 of 92 here — alongside 91 others — read 2 September 2026
가치투자클럽
@corevalue · 67,126
Telegram ranks this channel #53 of 93 here — alongside 92 others — read 2 September 2026
실시간 주식 뉴스
@realtime_stock_news · 36,964
Telegram ranks this channel #59 of 93 here — alongside 92 others — read 2 September 2026
여의도스토리 Ver2.0-习近平是个狗东西
@YeouidoStory2 · 57,966
Telegram ranks this channel #61 of 92 here — alongside 91 others — read 2 September 2026
신영증권 박소연
@sypark_strategy · 29,259
Telegram ranks this channel #64 of 91 here — alongside 90 others — read 8 September 2026
유진투자증권 코스닥벤처팀
@SmallCap · 22,994
Telegram ranks this channel #65 of 96 here — alongside 95 others — read 19 September 2026
주식 급등일보🚀급등테마·대장주 탐색기 | Korean Stocks
@FastStockNews · 128,822
Telegram ranks this channel #71 of 92 here — alongside 91 others — read 2 September 2026
[메리츠 Tech 김선우, 양승수, 김동관]
@merITz_tech · 24,795
Telegram ranks this channel #72 of 92 here — alongside 91 others — read 17 September 2026
이지스스트레티지 리서치
@jeilstock · 26,244
Telegram ranks this channel #84 of 93 here — alongside 92 others — read 12 September 2026

This channel appears in 10 seed channels' Telegram-generated recommendation lists in total. Each is Telegram’s list for THAT channel, not this one — see how this is measured.

Cite this entry

A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 9 November 2026 — this entry's latest reading, not the date you are reading this.

“허혜민의 제약/바이오 소식통” (@huhpharm), 24,265 subscribers as measured 9 November 2026. Telegram Register, tgregister.com/channel/huhpharm.

Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.